Pharmacologically Diverse Antidepressants Rapidly Activate Brain-Derived Neurotrophic Factor Receptor TrkB and Induce Phospholipase-Cγ Signaling Pathways in Mouse Brain
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Previous studies suggest that brain-derived neurotrophic factor and its receptor TrkB are critically involved in the therapeutic actions of antidepressant drugs. We have previously shown that the antidepressants imipramine and fluoxetine produce a rapid autophosphorylation of TrkB in the rodent brain. In the present study, we have further examined the biochemical and functional characteristics of antidepressant-induced TrkB activation in vivo. We show that all the antidepressants examined, including inhibitors of monoamine transporters and metabolism, activate TrkB rapidly in the rodent anterior cingulate cortex and hippocampus. Furthermore, the results indicate that acute and long-term antidepressant treatments induce TrkB-mediated activation of phospholipase-Cgamma1 (PLCgamma1) and increase the phosphorylation of cAMP-related element binding protein, a major transcription factor mediating neuronal plasticity. In contrast, we have not observed any modulation of the phosphorylation of TrkB Shc binding site, phosphorylation of mitogen-activated protein kinase or AKT by antidepressants. We also show that in the forced swim test, the behavioral effects of specific serotonergic antidepressant citalopram, but not those of the specific noradrenergic antidepressant reboxetine, are crucially dependent on TrkB signaling. Finally, brain monoamines seem to be critical mediators of antidepressant-induced TrkB activation, as antidepressants reboxetine and citalopram do not produce TrkB ac…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Research on the biological connections demonstrated that antidepressants activate the BDNF via tropomyosin receptor kinase B (TrkB) and a common transcription factor cAMP response element-binding protein (CREB; Koponen et al., 2005;Rantamaki et al., 2007).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Rantamaki et al., 2007
In the citing paper
“Antidepressant drugs require functional TrkB receptors to mediate antidepressant-like response in preclinical models (Rantamäki et al., 2007; Saarelainen et al., 2003).”
From BDNF - a key transducer of antidepressant effects (2016) · cites this paper as Rantamäki et al., 2007
In the citing paper
“Rather intriguingly, chronic antidepressant treatment increases the phosphorylation of the TrkB receptor, thus increasing its activity, in the hippocampus and anterior cingulate cortex suggesting that BDNF-TrkB signaling in these brain regions may be critical in mediating antidepressant effects (Rantamäki et al., 2007).”
From BDNF - a key transducer of antidepressant effects (2016) · cites this paper as Rantamäki et al., 2007
In the citing paper
“autophosphorylation of TrkB by antidepressants has also been reported by the group of Castren (Rantamaki et al. 2007; Saarelainen et al. 2003)”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Rantamaki et al. 2007
In the citing paper
“Other studies have found that antidepressants from a variety of chemical families (e.g., SSRIs, SNRIs, tricyclics, etc.) all increase activation of TrkB and its downstream effector CREB (140).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [140]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Neurotrophins: Roles in Neuronal Development and Function
Huang, E. J., & Reichardt, L. F. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.677 · Cited by 4,394
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 2×
“This FLX administration protocol has been previously shown to produce long-term alterations in neuroplasticity and animal behavior (Santarelli et al, 2003).”
InfluentialEgan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 1×
“Furthermore, val/met polymorphism in BDNF gene, which influences the activity-dependent BDNF release (Egan et al, 2003) has recently been associated with mood disorders in humans (Sklar et al, 2002; Lang et al, 2005).”
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 4×
“In addition, antidepressants block and accelerate the reversion of stress-induced downregulation in BDNF mRNA and protein, respectively (Nibuya et al, 1995; Xu et al, 2004).”
InfluentialBrain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654
Smith, M., Makino, S., Kvetnansky, R., & Post, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-03-01768.1995 · Cited by 1,440
CARLEZONJR, W., DUMAN, R., & NESTLER, E. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.06.005 · Cited by 1,346
Decreased serum brain-derived neurotrophic factor levels in major depressed patients
Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., & Aubry, J.-M. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(02)00005-7 · Cited by 1,232 · cited 1×
“BDNF levels are reduced in mood disorders and preclinical depression models, and long-term antidepressant treatment enhances brain BDNF gene expression and signaling (Nibuya et al, 1995, 1996; Smith et al, 1995; Russo-Neustadt et al, 1999; Chen et al, 2001b; Karege et al, 2002, 2005).”
Nibuya, M., Nestler, E., & Duman, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-07-02365.1996 · Cited by 1,206
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 2×
“PLCc1 Pathway Signal transduction pathways activated by chronic antidepressant treatments have been intensively investigated (Duman et al, 1997; Manji et al, 2001; Coyle and Duman, 2003), but less is known about the pathways that are activated acutely by antidepressants.”
Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication
Chen, B., Dowlatshahi, D., MacQueen, G. M., Wang, J.-F., & Young, L. T. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01083-6 · Cited by 1,164
BDNF and Activity-Dependent Synaptic Modulation: Figure 1.
Lu, B. (2003) · Learning & Memory · doi:10.1101/lm.54603 · Cited by 945
Antidepressant-like effect of brain-derived neurotrophic factor (BDNF)
Siuciak, J. A., Lewis, D. R., Wiegand, S. J., & Lindsay, R. M. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00169-4 · Cited by 841
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800
Self-citationEssential role of brain-derived neurotrophic factor in adult hippocampal function
Monteggia, L. M., Barrot, M., Powell, C. M., Berton, O., Galanis, V., Gemelli, T., Meuth, S., Nagy, A., Greene, R. W., & Nestler, E. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402141101 · Cited by 685 · cited 6×
“BDNF-mediated TrkB signaling appears to be critically involved in the behavioral effects of antidepressants in the rodent models of behavioral despair (Hoshaw et al, 2005; Monteggia et al, 2004; Koponen et al, 2005; Saarelainen et al, 2003; Shirayama et al, 2002; Siuciak et al, 1997).”
InfluentialRole of neurotrophic factors in depression
CASTREN, E., VOIKAR, V, & RANTAMAKI, T. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.009 · Cited by 667 · cited 2×
“…(BDNF), a member of the neurotrophin family of neurotrophic factors, and its primary receptor TrkB seem to be particularly relevant factors involved in both the development of mood disorders and the action of antidepressants (Altar, 1999; Nestler et al, 2002; Castrén, 2005; Castrén et al, 2007).”
Self-citationKarege, F., Bondolfi, G., Gervasoni, N., Schwald, M., Aubry, J.-M., & Bertschy, G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.008 · Cited by 593
Sklar, P., Gabriel, S. B., McInnis, M. G., Bennett, P., Lim, Y.-M., Tsan, G., Schaffner, S., Kirov, G., Jones, I., Owen, M., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001058 · Cited by 567
Castrén, E. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1629 · Cited by 563
Altar, C. A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01309-7 · Cited by 534
Depolarization and cAMP Elevation Rapidly Recruit TrkB to the Plasma Membrane of CNS Neurons
Meyer-Franke, A., Wilkinson, G. A., Kruttgen, A., Hu, M., Munro, E., Hanson, M. G., Reichardt, L. F., & Barres, B. A. (1998) · Neuron · doi:10.1016/s0896-6273(00)80586-3 · Cited by 516
cAMP Response Element-Mediated Gene Transcription Is Upregulated by Chronic Antidepressant Treatment
Thome, J., Sakai, N., Shin, K.-H., Steffen, C., Zhang, Y.-J., Impey, S., Storm, D., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04030.2000 · Cited by 508
Mechanism of TrkB-Mediated Hippocampal Long-Term Potentiation
Minichiello, L., Calella, A. M., Medina, D. L., Bonhoeffer, T., Klein, R., & Korte, M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00942-x · Cited by 506 · cited 7×
“Minichiello et al (2002) have recently shown that the Y816 site of TrkB, in contrast to Y515 site, is an important regulator of CREB phosphorylation in vitro.”
InfluentialMonteggia, L. M., Luikart, B., Barrot, M., Theobold, D., Malkovska, I., Nef, S., Parada, L. F., & Nestler, E. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.021 · Cited by 502 · cited 3×
“This is an interesting finding, as previous studies by Monteggia et al (2004, 2007) have shown that the behavioral effects of tricyclic antidepressant desipramine (shows more affinity against the NET compared with SERT) were absent in forebrain-specific conditional BDNF knockout mice.”
InfluentialExercise, Antidepressant Medications, and Enhanced Brain Derived Neurotrophic Factor Expression
Russo-Neustadt, A. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00059-7 · Cited by 411
Balkowiec, A., & Katz, D. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-23-10399.2002 · Cited by 405
Page, M. E., Detke, M. J., Dalvi, A., Kirby, L. G., & Lucki, I. (1999) · Psychopharmacology · doi:10.1007/s002130051156 · Cited by 385
Finding the Intracellular Signaling Pathways Affected by Mood Disorder Treatments
Coyle, J. T., & Duman, R. S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00195-8 · Cited by 360
Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects
Hoshaw, B. A., Malberg, J. E., & Lucki, I. (2005) · Brain Research · doi:10.1016/j.brainres.2005.01.007 · Cited by 348
Clinical Pharmacokinetics of Fluoxetine
Altamura, A. C., Moro, A. R., & Percudani, M. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426030-00004 · Cited by 336
Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor
Wong, E. H. F., Sonders, M. S., Amara, S. G., Tinholt, P. M., Piercey, M. F. P., Hoffmann, W. P., Hyslop, D. K., Franklin, S., Porsolt, R. D., Bonsignori, A., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00291-7 · Cited by 334
Bymaster, F. P., Zhang, W., Carter, P. A., Shaw, J., Chernet, E., Phebus, L., Wong, D. T., & Perry, K. W. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0986-x · Cited by 334
Conti, A. C., Cryan, J. F., Dalvi, A., Lucki, I., & Blendy, J. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03262.2002 · Cited by 328
Ji, Y., Pang, P. T., Feng, L., & Lu, B. (2005) · Nature Neuroscience · doi:10.1038/nn1381 · Cited by 325
Chen, A. C.-H., Shirayama, Y., Shin, K.-H., Neve, R. L., & Duman, R. S. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01114-8 · Cited by 314
Altar, C. A., Whitehead, R. E., Chen, R., Wörtwein, G., & Madsen, T. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00073-8 · Cited by 300
Berghuis, P., Dobszay, M. B., Wang, X., Spano, S., Ledda, F., Sousa, K. M., Schulte, G., Ernfors, P., Mackie, K., Paratcha, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509494102 · Cited by 291
Association of a functional BDNF polymorphism and anxiety-related personality traits
Lang, U. E., Hellweg, R., Kalus, P., Bajbouj, M., Lenzen, K. P., Sander, T., Kunz, D., & Gallinat, J. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2137-7 · Cited by 274
Cryan, J. F., O'Leary, O. F., Jin, S.-H., Friedland, J. C., Ouyang, M., Hirsch, B. R., Page, M. E., Dalvi, A., Thomas, S. A., & Lucki, I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401080101 · Cited by 252
MacQueen, G. M., Ramakrishman, K., Croll, S. D., Siuciak, J. A., Yu, G., Young, T., & Fahnestock, M. (2001) · Behavioral Neuroscience · doi:10.1037//0735-7044.115.5.1145 · Cited by 211
Lee, F. S., Rajagopal, R., Kim, A. H., Chang, P. C., & Chao, M. V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107421200 · Cited by 200
Self-citationTiraboschi, E., Tardito, D., Kasahara, J., Moraschi, S., Pruneri, P., Gennarelli, M., Racagni, G., & Popoli, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300488 · Cited by 186
Distinctive features of Trk neurotrophin receptor transactivation by G protein-coupled receptors
Lee, F. S., Rajagopal, R., & Chao, M. V. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00024-7 · Cited by 177
Self-citationMAP Kinase Activation by Fluoxetine and Its Relation to Gene Expression in Cultured Rat Astrocytes
Mercier, G., Lennon, A. M., Renouf, B., Dessouroux, A., Ramaugé, M., Courtin, F., & Pierre, M. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:2:207 · Cited by 176 · cited 1×
“Previous studies on the role of MAPK pathway in the mechanism of antidepressant action have yielded conflicting results (Mercier et al, 2004; Tiraboschi et al, 2004; Fumagalli et al, 2005).”
Haapasalo, A., Sipola, I., Larsson, K., Åkerman, K. E. O., Stoilov, P., Stamm, S., Wong, G., & Castrén, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205202200 · Cited by 171
Koponen, E., Võikar, V., Riekki, R., Saarelainen, T., Rauramaa, T., Rauvala, H., Taira, T., & Castrén, E. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.01.006 · Cited by 170 · cited 1×
“Furthermore, transgenic mice overexpressing TrkB receptors in brain show enhanced learning and increased PLCg1 pathway activity, but no change in the MAPK pathway (Koponen et al, 2004).”
Xu, H., Steven Richardson, J., & Li, X.-M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300009 · Cited by 167 · cited 1×
“Although some studies have reported upregulation of BDNF protein in the rodent hippocampus after prolonged antidepressant treatment (Xu et al, 2003; Wyneken et al, 2006), some studies have failed to see such significant alterations (Altar et al, 2003; Holoubek et al, 2004).”
Differential Utilization of Trk Autophosphorylation Sites
Segal, R. A., Bhattacharyya, A., Rua, L. A., Alberta, J. A., Stephens, R. M., Kaplan, D. R., & Stiles, C. D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.20175 · Cited by 160
Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain
Zetterström, T., Pei, Q., Madhav, T. R., Coppell, A., Lewis, L., & Smith, A. D. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00022-2 · Cited by 143
Koponen, E., Rantamäki, T., Voikar, V., Saarelainen, T., MacDonald, E., & Castrén, E. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-005-8468-z · Cited by 125
Self-citationYagasaki, Y., Numakawa, T., Kumamaru, E., Hayashi, T., Su, T.-P., & Kunugi, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508157200 · Cited by 122 · cited 2×
“This finding is supported by the recent observation that pretreatment of primary cortical cultures with imipramine augment BDNF-induced association of TrkB with PLCg1 and thus increases the activation of PLCg1 (Yagasaki et al, 2006).”
Fumagalli, F., Molteni, R., Calabrese, F., Frasca, A., Racagni, G., & Riva, M. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03149.x · Cited by 111
Saarelainen, T., Lukkarinen, J. A., Koponen, S., Gröhn, O. H. J., Jolkkonen, J., Koponen, E., Haapasalo, A., Alhonen, L. I., Wong, G., Koıstınaho, J., et al. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0863 · Cited by 106
Itoh, T., Tokumura, M., & Abe, K. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.084 · Cited by 103
Laifenfeld, D., Karry, R., Grauer, E., Klein, E., & Ben-Shachar, D. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.023 · Cited by 103
Du, J., Feng, L., Zaitsev, E., Je, H.-S., Liu, X.-W., & Lu, B. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305134 · Cited by 100
Page, M. E. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00301-9 · Cited by 90
Carter, B. D., Zirrgiebel, U., & Barde, Y.-A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.37.21751 · Cited by 89
Pozzi, L., Invernizzi, R., Garavaglia, C., & Samanin, R. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731051.x · Cited by 86
Xu, H., Luo, C., Richardson, J. S., & Li, X.-M. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500265 · Cited by 81
Frechilla, D., Otano, A., & Río, J. D. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(98)00040-2 · Cited by 73
Rantamäki, T., Knuuttila, J. E. A., Hokkanen, M., & Ċastrén, E. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.10.001 · Cited by 63
Self-citationWeinstock, M., Poltyrev, T., Bejar, C., & Youdim, M. B. H. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0978-x · Cited by 61
Airavaara, M., Mijatovic, J., Vihavainen, T., Piepponen, T. P., Saarma, M., & Ahtee, L. (2006) · Synapse · doi:10.1002/syn.20245 · Cited by 51
Self-citationO’Leary, O. F., Bechtholt, A. J., Crowley, J. J., Valentino, R. J., & Lucki, I. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.06.012 · Cited by 48
Kankaanpää, A., Meririnne, E., Ariniemi, K., & Seppαlä, T. (2001) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)00553-3 · Cited by 45
Self-citationDrago, F., Nicolosi, A., Micale, V., & Menzo, G. L. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00084-0 · Cited by 40
Wyneken, Ú., Sandoval, M., Sandoval, S., Jorquera, F., González, I., Vargas, F., Falcon, R., Monari, M., & Orrego, F. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301052 · Cited by 35
Neurotrophin-4 mediated TrkB activation reinforces morphine-induced analgesia
Lucas, G., Hendolin, P., Harkany, T., Agerman, K., Paratcha, G., Holmgren, C. D., Zilberter, Y., Sairanen, M., Minichiello, L., Ċastrén, E., et al. (2003) · Nature Neuroscience · doi:10.1038/nn1021 · Cited by 23
Self-citationHoloubek, G., Nöldner, M., Treiber, K., & Müller, W. E. G. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832664 · Cited by 21
Identification and Characterization of Compounds That Potentiate NT-3-Mediated Trk Receptor Activity
Lewis, M. A., Hunihan, L., Franco, D., Robertson, B., Palmer, J., Laurent, D. R. S., Balasubramanian, B. N., Li, Y., & Westphal, R. S. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.020255 · Cited by 21 · cited 1×
“Finally, as NT-3 (and NT-4/5) is a low-affinity ligand for TrkB, antidepressants may induce TrkB activation by enhancing the effects of this neurotrophin (see Lewis et al, 2006).”
Cited by
Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders
Autry, A. E., & Monteggia, L. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005108 · Cited by 1,390
“In a subsequent study, antidepressant drugs were found to rapidly activate the TrkB receptor and PLC signaling, which suggests that this intracellular pathway is a common mechanism for antidepressant drug action (Rantamäki et al., 2007).”
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
BDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958
“…of BDNF signaling in the response to antidepressants has come from studies examining the high affinity BDNF receptor, TrkB. Antidepressant drugs require functional TrkB receptors to mediate antidepressant-like response in preclinical models (Rantamäki et al., 2007; Saarelainen et al., 2003).”
BackgroundCastrén, E., & Rantamäki, T. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20758 · Cited by 864
Self-citationAntidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
Self-citation
Metadata
- Authors
- Rantamäki, T., Hendolin, P., Kankaanpää, A., Mijatovic, J., Piepponen, P., Domenici, E., Chao, M. V., Männistö, P. T., & Castrén, E.
- Affiliations
- University of Helsinki (FI)
- GlaxoSmithKline (Italy) (IT)
- NYU Langone Health (US)
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2007-02-21
- Volume
- 32
- Issue
- 10
- Pages
- 2152-2162
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2064468814
- Cited by
- 305
- References
- 75
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 18 · 2023: 17 · 2022: 15 · 2021: 15 · 2020: 18 · 2019: 18 · 2018: 14 · 2017: 20 · 2016: 13 · 2015: 16 · 2014: 15 · 2013: 18 · 2012: 20
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Iris (University of Trento) (submittedVersion)
- Funders
- GlaxoSmithKline
- Academy of Finland
- Suomen Kulttuurirahasto
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- antidepressants, TrkB receptor, brain-derived neurotrophic factor, phospholipase C-gamma1, CREB, monoamine transporters, citalopram, reboxetine, serotonin depletion, norepinephrine depletion, anterior cingulate cortex, hippocampus, forced swim test, monoamine signaling
- MeSH terms
- Reboxetine, Animals, Antidepressive Agents, Binding Sites, Brain, Brain Chemistry, Depressive Disorder, Gyrus Cinguli, Hippocampus, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Morpholines, Phosphorylation, Citalopram, Signal Transduction, Up-Regulation, Cyclic AMP Response Element-Binding Protein, Selective Serotonin Reuptake Inhibitors, Adrenergic Uptake Inhibitors, Brain-Derived Neurotrophic Factor, Receptor, trkB, Mice, Phospholipase C gamma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.